TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 | Nov 03, 2025

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027.

Twitter -   / i101in  

#earningscall #StockMarketNews

If you want us to remove your company's earnings call or any other conference call, please reach out to [email protected].